A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes

NCT02212067 · Completed

Last updated 2026-05-28

This clinical trial is testing the effects of semaglutide, a medication, on insulin production in people with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 87 people

Who can join Ages 18–64 · all sexes

Timeline Started 2014-08 · est. completion 2015-05

Where 1 site · Germany

What this study is testing ClinicalTrials.gov NCT02212067 ↗

Description as written by the study sponsor.

This trial is conducted in Europe. The aim of the trial is to investigate the effects of semaglutide on ß-cell function in subjects with type 2 diabetes.

Treatments tested

semaglutide Drug

Administered subcutaneously (s.c., under the skin) once weekly for 12 weeks.
placebo Drug

Administered subcutaneously (s.c., under the skin) once weekly for 12 weeks.

Main thing measured	Area under the serum insulin concentration time curve from 0 to 10 minutes after a 25 g glucose bolus i.v. infusion (IVGTT,intravenous glucose tolerance test) over 2 minutes
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02212067 ↗